HEXO:TSX-Hexo Corp (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 0.22

Change

0.00 (0.00)%

Market Cap

CAD 0.13B

Volume

0.30M

Avg Analyst Target

CAD 0.24 (+9.09%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


HEXO Stock Forecast & Price:
Based on the Hexo Corp stock forecasts from 5 analysts, the average analyst target price for Hexo Corp is CAD 0.24 over the next 12 months. Hexo Corp’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Hexo Corp is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Hexo Corp’s stock price was CAD 0.22. Hexo Corp’s stock price has changed by -2.22% over the past week, -12.00% over the past month and -84.40% over the last year.

About Hexo Corp (HEXO:CA:TSX)

HEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
APHA:CA Aphria Inc

N/A

CAD4.44B 57.08 598.01
BHC:CA Bausch Health Companies Inc

+0.14 (+1.54%)

CAD3.30B 9.50 9.84
TLRY:CA Tilray Inc

+0.13 (+2.64%)

CAD3.14B 9.60 -11.75
WEED:CA Canopy Growth Corp

+0.07 (+1.53%)

CAD2.23B N/A -0.96
CRON:CA Cronos Group Inc

+0.09 (+2.22%)

CAD1.54B 46.76 -1.36
GUD:CA Knight Therapeutics Inc

-0.03 (-0.56%)

CAD0.61B 41.51 15.40
ACB:CA Aurora Cannabis Inc

+0.01 (+0.60%)

CAD0.55B 1,171.00 -0.31
OGI:CA OrganiGram Holdings Inc

+0.08 (+6.11%)

CAD0.41B -99,999.99 -851.42
HLS:CA HLS Therapeutics Inc

-0.04 (-0.41%)

CAD0.30B N/A 20.25
DHT-UN:CA DRI Healthcare Trust

+0.65 (+9.22%)

CAD0.29B 11.85 N/A

ETFs Containing HEXO:CA

Symbol Name Weight Mer Price(Change) Market Cap
SEED:CA Evolve Marijuana Fund 0.00 % 0.75 %

N/A

CAD3.63M

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -75.00% 14% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.00% 14% F 2% F
Trailing 12 Months  
Capital Gain -84.51% 7% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -84.51% 7% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -34.67% 24% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.67% 24% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 66.12% 17% F 12% F
Risk Adjusted Return -52.43% 62% D- 14% F
Market Capitalization 0.13B 63% D 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.42 87% B+ 93% A
Price / Cash Flow Ratio -1.13 47% F 73% C
EV/EBITDA -0.29 46% F 71% C-
Management Effectiveness  
Return on Equity -205.29% 10% F 3% F
Return on Invested Capital -117.82% 25% F 3% F
Return on Assets -14.48% 33% F 10% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 21.32 17% F 7% F
Short Percent 4.28% 12% F 20% F
Beta 1.85 37% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector